Tuberc Respir Dis.  2002 Jun;52(6):590-596.

Comparison of OK-432 and Doxycycline Pleurodesis for Malignant Pleural Effusions Caused by Lung Cancer

• Chung JH
• Park MS
• Cheong JH
• Kim YS
• Chang J
• Kim JH
• Kwak SM
• Kim SK
• Kim SK

Abstract

BACKGROUND: Lung cancer is the leading cause of malignant pleural effusions, which is currently most commonly treated using pleurodesis via bedside thoracostomy. Several agents had been used for the treatment of pleural sclerosis, but with differing efficacies and associated side effects. Our purpose with this study was to compare the efficacy, side effects and disease free survival times of patients being treated with OK-432 and doxycycline sclerotherapy in lung cancer induced malignant pleural effusions.
PATIENTS AND METHODS
79 patients who underwent pleurodesis with OK-432 and doxycycline, between Jan. 1994 and Aug. 2001, were retrospectively reviewed. Resopnses 30 days following pleurodesis were determined from chest radiographs, with the disease free survival time being evaluated according to the response.
RESULTS
The success rates, 30 day followint pleurodesis, with OK-432 and doxycycline 83 and 87%, respectively (p=0.677). With regard to the side effects, fever was more common when OK-432 was used (59%, p=0.001), and pain was more common with doxycycline use (73%, p=0.008). There was no significant difference in disease free survival times between OK-432 (13.6 Months) and doxycycline (11.6 Months) (p=0.532).
CONCLUSION
with the use of OK-432, for pleurodesis, was as effective as doxycycline, can be considered as an alternative treatment for malignant effusion in patients with lung cancer.

Keyword

OK-432; Doxycycline; Pleurodesis

MeSH Terms

Disease-Free Survival
Doxycycline*
Fever
Humans
Lung Neoplasms*
Lung*
Picibanil*
Pleural Effusion, Malignant*
Pleurodesis*
Radiography, Thoracic
Retrospective Studies
Sclerosis
Sclerotherapy
Thoracostomy
Doxycycline
Picibanil